Sciomics offers a high-content analysis services for combined phosphorylation / ubiquitinylation and protein analysis to investigate pathway activity, disease mechanisms, drug mode-of-action or discover novel drug targets and biomarkers. Currently, more than 1,000 proteins, many being keyplayers in biomedical pathways are analysed in parallel by our immuno-based antibody array platform. The platform guarantees robust and reproducible results which can easily be translated in clinical assays.
In addition to these CRO activities, Sciomics is active in the early-phase development of novel diagnostic means for precision medicine with a focus on cancer as well as organ failure. These activities are based on the very same platform, which was developed by the founders at the German Cancer Research Center (DKFZ) during the past 15 years.
Karl-Landsteiner Str. 6
69151 Neckargemuend bei Heidelberg